Mercury Laboratories Ltd. Stock Analysis 538964.BO

Mercury Laboratories Ltd. engages in the production and sale of pharmaceuticals and its related products. The company is headquartered in Vadodara, Gujarat and currently employs 503 full-time employees. The company went IPO on 2015-02-23. The firm operates through the Pharmaceuticals Products segment. The company is engaged in the manufacturing and export of a range of pharmaceutical items. The products of the Company are in the segment of gynecology and pediatrics. Its products include antibiotic, antifungal, and antiviral formulations; anti-inflammatory formulations; antimalarial formulations; digestive formulations; hypoglycemic formulations; multivitamin formulations; central nervous system formulations; gynec formulations; CVS formulations; cough and cold formulations; and miscellaneous formulations, and innovative products. Its antibiotic, antifungal, and antiviral formulations include azithromycin tablets, azithromycin dispersible tablets, griseofulvin tablets, metronidazole tablets, and others. Its anti-inflammatory formulations include dexamethasone tablets, glucosamine sulphate tablets, dexamethasone sodium phosphate injection, and others.